ABSTRACT
The isolation, and subsequent chemical, pharmacological and toxicological characterisation of galanthamine, is described in the previous chapter of this volume, together with a summary of trials in indications other than Alzheimer’s Disease (AD). This chapter reviews the early trials of galanthamine in AD and provides detail, where it is available, of ongoing clinical research with the compound. For a review of the animal work underpinning this application, the reader is referred to the previous chapter.
